This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-17 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Juergen Mueller, PhD
Commercial Director Nucleic Acid Therapeutics (NAT) at LGC Axolabs

Profile


Juergen is currently Commercial Director NAT (Nucleic Acid Therapeutics) at LGC Axolabs, covering the commercial and sales responsibility for all clinical service programs in the Oligo-therapeutics field within LGC.  This includes worldwide marketing & sales responsibity since LGC serves clients in EU, US (North America including Canada and South America), and APAC region. Juergen spend more than >20  years in the Life Science industry while having held senior management positions in BD, Sales and Marketing, Licensing and Project Management from Fortune  500 companies, such as Sigma-Aldrich (US), up to service providers as Solvias (CH), and leading Oligo CMO’s as Nitto-Avecia (US/Jpn).  Drug development experience as CSO for Syndeco (CH) while developing small molecule and peptide NCE’s from lead to clinical candidates. Author and inventor of >40 peer reviewed scientific articles and patents.

Agenda Sessions

  • LGC’s NAT Extended Services: Physicochemical Property Characterization of an Oligonucleotide

    11:35